Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C news

Show

From To
Harm reduction approaches predicted to reduce rates of new hepatitis C infection for people who inject drugs

A combination of providing clean needles and syringes and offering safer oral therapy, such as methadone, reduced the predicted risk of becoming infected with hepatitis C virus by 71%. Providing both services to people who inject drugs was likely to be cost-effective and has the potential to be cost-saving in some parts of the UK, depending on the size of the local population of people who inject drugs and underlying rates of infection.

Published
08 December 2017
From
National Institute for Health Research
MSF: People co-infected with HIV to receive hepatitis C treatment in Mykolaiv region

Medecins Sans Frontieres (MSF) has begun treatment for hepatitis C with people who are co-infected with hepatitis C and HIV in Mykolaiv region, in southern Ukraine, where prevalence of HIV is two times higher than the average across the country.

Published
04 December 2017
From
UNIAN
Gilead prices hepatitis C giant Sovaldi in China at one-fifth the US price: report

It was expected that Gilead would deeply discount Sovaldi for the Chinese market, but the reported price is still much higher than in other emerging markets where it has licensed the drug to generics makers.

Published
29 November 2017
From
FiercePharma
How Drug Users Would Solve the Opioid Crisis

Users say they want to end prohibition, seek reparations, and get invested in pain alternatives like weed. In Vancouver, that’s already happening.

Published
15 November 2017
From
Vice
Nine countries now on track to eliminate hepatitis

New data on hepatitis C released by the Polaris Observatory and presented today at the World Hepatitis Summit (WHS) in Sao Paulo, Brazil show that nine countries — Australia, Brazil, Egypt, Georgia, Germany, Iceland, Japan, the Netherlands and Qatar — are on course to eliminate hepatitis C by 2030.

Published
01 November 2017
From
World Hepatitis Summit
MSF Secures Deals For Key Hepatitis C Medicines, Price A Fraction Of Branded Drug

Médecins Sans Frontières (MSF, Doctors Without Borders) announced today that it has secured deals for two key generic hepatitis C medicines, sofosbuvir and daclatasvir, for as low as US$1.40 per day, or US$120 per 12-week treatment course.

Published
31 October 2017
From
Intellectual Property Watch
Close to 3 million people access hepatitis C cure

On the eve of the World Hepatitis Summit in Brazil, WHO reports increasing global momentum in the response to viral hepatitis. A record 3 million people were able to obtain treatment for hepatitis C over the past two years, and 2.8 million more people embarked on lifelong treatment for hepatitis B in 2016.

Published
31 October 2017
From
World Health Organization
Gilead HCV drug sales down in 2017 third quarter compared with 2016

Gilead announced that combined third-quarter sales for Harvoni, Sovaldi, Epclusa and Vosevi were $2.2 billion compared with $3.3 billion the third quarter of 2016, related to fewer patients initiating treatment and increased drug competition.

Published
31 October 2017
From
Healio
More than 6 million treated for hepatitis globally

Since 2015, nearly 3 million people initiated treatment for hepatitis C, and in 2016 alone nearly 3 million initiated hepatitis B treatment, according to an announcement from the World Health Organization in conjunction with the World Hepatitis Summit.

Published
31 October 2017
From
Healio
Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty

A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment.

Published
26 October 2017
From
Intellectual Property Watch
← First12345...131Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.